Posted in | News | Biomaterials | Chemistry

ProMetic Signs Deal to Improve Production Process of Biopharmaceutical Product

Related Stories

ProMetic Life Sciences declared that its UK subsidiary company, ProMetic Biosciences, has inked a deal with a global company to improve the quality of its current biopharmaceutical product produced in huge quantities.

ProMetic, as per deal, will improve the efficiency of an affinity resin product and the related production process specifications for its client. The services offered by ProMetic will enable the client to manufacture the product with improved capabilities to achieve more market share in the growing market. The deal will allow Prometic to receive CAD 800,000 as initial income during the year 2011. The company, after accomplishing the associated target product profiles, anticipates entering into a long term accord for the production and distribution of the affinity resin.

According to Dr. Steve Burton, CEO of ProMetic Biosciences, the affinity technology supplied by the company has a number of potential uses. This has been shown in the latest application where a specifically designed affinity product will be deployed to take out particular impurities from a biopharmaceutical product to improve its safety and quality. He added that the increased annual production of the biopharmaceutical product and the regularity of large production will prompt a continuous demand for ProMetic’s resin product.

Source:

http://www.prometic.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chai, Cameron. (2019, February 09). ProMetic Signs Deal to Improve Production Process of Biopharmaceutical Product. AZoM. Retrieved on November 24, 2024 from https://www.azom.com/news.aspx?newsID=29346.

  • MLA

    Chai, Cameron. "ProMetic Signs Deal to Improve Production Process of Biopharmaceutical Product". AZoM. 24 November 2024. <https://www.azom.com/news.aspx?newsID=29346>.

  • Chicago

    Chai, Cameron. "ProMetic Signs Deal to Improve Production Process of Biopharmaceutical Product". AZoM. https://www.azom.com/news.aspx?newsID=29346. (accessed November 24, 2024).

  • Harvard

    Chai, Cameron. 2019. ProMetic Signs Deal to Improve Production Process of Biopharmaceutical Product. AZoM, viewed 24 November 2024, https://www.azom.com/news.aspx?newsID=29346.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
(Logout)
Your comment type
Submit

Sponsored Content

Editorial Highlights

The Current State of the Global Semiconductor Market

The Current State of the Global Semiconductor Market

The global semiconductor market has entered an exciting period. Demand for chip technology is both driving the industry as well as hindering it, with current chip shortages predicted to last for some time. Current trends will likely shape the future of the industry, which is set to continue to show

How are Graphene Batteries Made?

How are Graphene Batteries Made?

The primary distinction between graphene-based batteries and solid-state batteries lies in the composition of either electrode. Although the cathode is commonly changed, carbon allotropes can also be employed in fabricating anodes.

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback